利妥昔单抗诱导后格拉替雷治疗复发型多发性硬化
结果显示利妥昔单抗组无疾病活动证据比例更高(44.44% vs 19.23%,p=0.049),但获益在研究期内减退。
要点
- 利妥昔单抗诱导后格拉替雷治疗可短期提高无疾病活动证据比例。
- 利妥昔单抗组治疗失败比例更低且失败时间更长。
- 两组不良事件无差异,但获益随时间减退。
核心结论
- 利妥昔单抗诱导后格拉替雷治疗在短期内可能优于单用格拉替雷,但获益在研究期内减退。
主要发现
- 研究结束时利妥昔单抗组44.44%达到无疾病活动证据,安慰剂组为19.23%(p=0.049)。
- 利妥昔单抗组治疗失败比例37.04%,安慰剂组69.23%(p=0.019)。
- 利妥昔单抗组治疗失败时间23.32个月,安慰剂组11.29个月(p=0.027)。
- 利妥昔单抗组新发病灶比例25.93%,安慰剂组61.54%(p=0.009)。
- 利妥昔单抗组新发T2病灶数0.48,安慰剂组1.96(p=0.027)。
临床怎么用
- 对于活动性复发型多发性硬化,可考虑利妥昔单抗诱导后格拉替雷治疗以短期提高无疾病活动证据比例。
- 需注意该获益在研究期内可能减退,应监测疾病活动并评估长期治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine whether rituximab induction followed by glatiramer acetate (GA) monotherapy is more effective than GA alone for the treatment of relapsing multiple sclerosis with active disease. METHODS: This was a single-center, double-blind, placebo-controlled study. Fifty-five participants were randomly assigned (1:1 ratio) to either rituximab (R-GA) or placebo (P-GA) induction, followed by GA therapy initiated in all participants. Participants were followed up to 3 years. The primary endpoint was the number of participants with no evidence of disease activity (NEDA): those without relapse, new MRI lesions, and sustained change in disability. RESULTS: Twenty-eight and 27 participants received rituximab and placebo induction, respectively, with one participant in each arm withdrawing before 6-month MRI. There were no significant differences in baseline characteristics. At end of study, 44.44% of R-GA participants demonstrated NEDA vs 19.23% of P-GA participants (p = 0.049). Treatment failed for a smaller proportion of R-GA participants (37.04% R-GA vs 69.23% P-GA, p = 0.019), and time to treatment failure was longer (23.32 months R-GA vs 11.29 months P-GA, p = 0.027). Fewer participants in the R-GA arm had new lesions (25.93% R-GA vs 61.54% P-GA, p = 0.009), and there were fewer new T2 lesions (0.48 R-GA vs 1.96 P-GA, p = 0.027). Probability of demonstrating NEDA in the R-GA arm returned to baseline within the study period. There were no differences in adverse events. CONCLUSIONS: Induction therapy with rituximab followed by GA may provide superior efficacy in the short term than GA alone in relapsing multiple sclerosis, but this benefit appears to wane within the study period. Larger studies are needed to assess sustainability of results. CLINICALTRIALSGOV IDENTIFIER: NCT01569451.
引用
- Honce JM, Nair KV, Sillau S, et al. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019. PMID: 30635477. doi:10.1212/WNL.0000000000006916
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。